A Study of Vaccine Therapy for Prostate Cancer Using Prostate Stem Cell Antigen (PSCA)-Transfected Dendritic Cells

使用前列腺干细胞抗原（PSCA）转染的树突状细胞进行前列腺癌疫苗治疗的研究

• 批准号: 14571527
• 负责人: DOI Hiroshi
• 金额: $ 2.18万
• 依托单位: Kansai Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2002
• 资助国家: 日本
• 起止时间: 2002 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14571527/
• 关键词: prostate stem cell antigen; genetic immunotherapy; prostate cancer

To establish genetic immunotherapy for prostate cancer, using prostate stem cell antigen (PSCA) as a specific antigen, we previously cloned cDNA of mPSCA from mouse prostate glands using RT-PCR and attempted DNA vaccine therapy, with mouse prostate cancer cell lines (RM-1 and RM-11) serving as target cells. These previous studies indicated the necessity of establishing some other evaluation systems for the expression of mPSCA protein in mouse prostate cancer cell lines. To meet this need, we prepared, using retrovirus vectors, RM-1 cells (RM-1mPSCA, RM-1FLAGmPSCA) and RM-11 cells (RM-11mPSCA, RM-11FLAGmPSCA) which permanently express mPSCA or FLAG-conjugated mPSCA.The present study was undertaken to evaluate the usefulness of these cells as an evaluation system. To this end, differences in cell proliferation depending on the presence or absence of mPSCA and FLAGmPSCA expression were investigated in vitro. The proliferation of RM-1mPSCA, RM-1FLAGmPSCA, RM-11mPSCA and RM-11FLAGmPSCA depicted a curve similar to that of RM-1 and RM-11 proliferation. Then, proliferation of the cells was evaluated in vivo. Mice were subcutaneously implanted with RM-1, RM-1mPSCA or RM-1FLAGmPSCA and their proliferation was examined. No marked difference in proliferation was noted among these tumor cell lines.Thus, it was possible to compare the expression of these cell lines at the protein level. We may therefore say that this mouse model is useful for evaluation of DNA vaccine therapy or RNA vaccine therapy for prostate cancer, with mPSCA serving as the target.

为了建立前列腺癌的遗传免疫疗法，使用前列腺干细胞抗原（PSCA）作为特定抗原，我们先前使用RT-PCR和尝试的DNA疫苗疗法和尝试使用小鼠前列腺癌细胞系（RM-1和RM-11和RM-11）（RM-1和RM-11）从小鼠前列腺中克隆了MPSCA的cDNA。这些先前的研究表明，有必要建立一些其他评估系统，以表达小鼠前列腺癌细胞系中MPSCA蛋白的表达。为了满足这种需求，我们使用逆转录病毒矢量，RM-1细胞（RM-1MPSCA，RM-1FLAGMPSCA）和RM-11细胞（RM-11MPSCA，RM-11MPSCA，RM-11FLAGMPSCA）准备了这些细胞，以评估这些细胞作为评估系统。为此，研究了在体外研究细胞增殖的差异，具体取决于MPSCA和FlagMPSCA表达的不存在。 RM-1MPSCA，RM-1FLAGMPSCA，RM-11MPSCA和RM-11FLAGMPSCA的增殖描绘了与RM-1和RM-11增殖相似的曲线。然后，在体内评估细胞的增殖。将小鼠皮下植入RM-1，RM-1MPSCA或RM-1FlagMPSCA，并检查了它们的增殖。在这些肿瘤细胞系中没有明显的增殖差异。因此，可以比较这些细胞系在蛋白质水平上的表达。因此，我们可能会说，该小鼠模型可用于评估前列腺癌的DNA疫苗疗法或RNA疫苗治疗，而MPSCA作为靶标。